|
|
|
| 全部(n = 288) | 有irAEs (n = 101) | 无irAEs (n = 187) | P值 |
| 性别，n (%) |
|
|
|
| ||
| 男性 |
| 214 (74.31) | 74 (73.27) | 140 (74.89) | 0.77 | |
| 女性 |
| 74 (25.69) | 27 (26.73) | 47 (25.13) | ||
| 年龄，n (%) |
|
|
|
| ||
| < 65 |
| 152 (52.78) | 56 (55.45) | 96 (51.34) | 0.51 | |
| ≥65 |
| 136 (47.22) | 45 (44.55) | 91 (48.66) | ||
| ECOG PS, n (%) |
|
|
|
| ||
| 0 |
| 43 (14.93) | 17 (16.83) | 26 (13.90) | 0.80 | |
| 1 |
| 211 (73.26) | 72 (71.29) | 139 (74.33) | ||
| 2 |
| 34 (11.81) | 12 (11.88) | 22 (11.77) | ||
| 瘤种，n (%) |
|
|
|
| ||
| 肺癌 | 143 (49.65) | 54 (53.47) | 89 (47.59) | 0.29 | ||
| 胃癌 | 29 (10.07) | 10 (9.90) | 19 (10.16) | |||
| 结直肠癌 | 22 (7.64) | 6 (5.94) | 16 (8.56) | |||
| 食管癌 | 15 (5.21) | 3 (2.97) | 12 (6.42) | |||
| 头颈部恶性肿瘤 | 15 (5.21) | 7 (6.93) | 8 (4.28) | |||
| 肝癌 | 12 (4.17) | 4 (3.96) | 8 (4.28) | |||
| 女性生殖系统肿瘤 | 12 (4.17) | 4 (3.96) | 8 (4.28) | |||
| 尿路上皮癌 | 11 (3.82) | 4 (3.96) | 7 (3.74) | |||
| 胰腺癌 | 11 (3.82) | 1 (0.99) | 10 (5.35) | |||
| 胆道恶性肿瘤 | 7 (2.43) | 4 (3.96) | 3 (1.60) | |||
| 乳腺癌 | 6 (2.08) | 3 (2.97) | 3 (1.60) | |||
| 恶性黑色素瘤 | 6 (2.08) | 3 (2.97) | 3 (1.60) | |||
| 胸腺纵隔恶性肿瘤 | 5 (1.74) | 0 | 5 (2.67) | |||
| 肉瘤 | 2 (0.69) | 2 (1.98) | 0 | |||
| 多原发肿瘤 | 8 (2.78) | 4 (3.96) | 4 (2.14) | |||
| 基线情况，n (%) |
|
|
|
| ||
| 无 |
| 187 (64.93) | 72 (71.29) | 115 (61.50) | 0.24 | |
| 有，但不全 |
| 69 (23.96) | 19 (18.81) | 50 (26.74) | ||
| 有且完全 |
| 32 (11.11) | 10 (9.90) | 22 (11.76) | ||
| PD-1抑制剂种类 |
|
|
|
| ||
| 信迪利单抗 |
| 100 (34.72) | 30 (29.70) | 70 (37.43) |
| |
| 特瑞普利单抗 |
| 57 (19.79) | 27 (26.73) | 30 (16.04) | ||
| 卡瑞丽珠单抗 |
| 49 (17.01) | 18 (17.82) | 31 (16.58) | 0.11 | |
| 替雷丽珠单抗 |
| 38 (13.20) | 8 (7.92) | 30 (16.04) | ||
| 帕博丽珠单抗 |
| 23 (7.99) | 10 (9.90) | 13 (6.95) |
| |
| 纳武利尤单抗 |
| 21 (7.29) | 8 (7.92) | 13 (6.95) | ||